[1] |
CHEN Xiao, GUO Xiaojing, XU Jinfang, WEI Lianhui, CHEN Chenxin, LIANG Jizhou, ZHENG Yi, YE Xiaofei.
Machine learning method in the detection of adverse drug reaction signals of brigatinib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 639-645.
|
[2] |
WEI Lianhui, ZHANG Pengpeng, LIU Yongmei, GUO Xiaojing, XU Jinfang, CHEN Xiao, CHEN Chenxin, YE Xiaofei.
Overlap weighting in detection of adverse drug reaction signals: a simulated study
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 646-650.
|
[3] |
CHEN Chenxin, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, HE Jia.
Combination of zero-inflated model and Dirichlet process in detection of adverse reaction signals during post-marketing surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 651-654.
|
[4] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[5] |
WANG Tiezhu.
Signal detection and analysis of adverse reaction of hydroxychloroquine sulfate induced visual impairment
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 657-660.
|
[6] |
CHEN Chao, ZHAO Yunfei, WANG Changzhi, GONG Lixiong, LIU Wei.
VigiRank prediction model of Uppsala monitoring center
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 270-274.
|
[7] |
ZHOU Ruiou, JI Huanhuan, GONG Li, ZHANG Ni, SONG Lin.
Detection and evaluation of adverse event signals of ribavirin, lopinavir / ritonavir and chloroquine phosphate based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 205-209.
|
[8] |
SUN Xuelin, QIAN Dongfang, TAN Siyuan, ZHANG Zixuan, HU Xin, ZHANG Yatong.
Comparative study on drug signal detection and evaluation at home and abroad
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1218-1222.
|
[9] |
LIU Jing, YE Guoju, WANG Qiming, LIU Wei, ZHAO Dafang, SUN Jun, LI Guoliang, WANG Xinmin, LI Ming.
Detection of report signals of adverse drug reactions by fuzzy BCPNN
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1113-1117.
|
[10] |
LYU Qiang, YAN Jiayang, ZHANG Wangzheqi, YE Xiaofei, GUO Xiaojing.
Safety of an Anti-novel Coronavirus Pneumonia Drug:Chloroquine Phosphate
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 110-114.
|
[11] |
GONG Li, PAN Lingyun, LIU Yan, JI Huanhuan, TANG Xuewen, JIA Yuntao.
Detection and Evaluation of Post-marketing Safety Alert Signals for Human Papillomavirus 9-valent Vaccine Based on US Vaccine Adverse Event Reporting System (VAERS)
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 478-486.
|
[12] |
WANG Tao, DONG Duo, XIONG Weiyi, TIAN Chunhua, LIU Hongliang.
Risk Signals of Innovative Antineoplastic Drug Chidamide Tablets
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(10): 614-616.
|
[13] |
WEI Jian-xiang, ZHANG Jian-yin, LIU Mei-han, LI Ming, SUN Jun, XU Hou-ming.
Study on Data Masking Effect Reduction Method for Adverse Drug Reaction Based on Hybrid Model
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 343-347.
|
[14] |
LI Jiang-fan, XUE Wei, HU Xin, LI Ke-xin.
Revelation of French BIA 10-2474 Clinical Trials to Chinese Investigators
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(2): 94-97.
|
[15] |
YAN Xin-yuan, WANG Yin-cheng, ZHANG Tian-yi, YE Xiao-fei, HOU Yong-fang, WU Gui-zhi, HE Jia.
Application of Time-to-onset in Drug Safety Surveillance
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(6): 350-352.
|